Outlook Therapeutics Inc (OTLK)

[pfelgueiras]

Today OTLK +17% Now at $2,36
Institutional Holders increasing their positions, new Institutional Holders buying, and also shorts closing their positions.
Lets squeeze the shorts.

My sugestion Bullish and Long for 1 or 2 years is OTLK
PRICE TARGETS: (Zacks+Nasdaq+TipRanks $5,00) ; (Barchart [Strong Buy]+ MarketBeat+CNN+WallStreetZen $6,00) ; Yahoo $4,88 ; MarketWatch $6,00/$5,00/$3,50) COVERTURE: Ladenburg Thalmann $9,00 ; Oppenheimer $12,00 Outperformer
Institucionais Sabby Managment, Vanguard, Armistice, Geode Capital, Two Sigma.

https://ir.outlooktherapeutics.com/.../a08b36df-0cdb-4c11...

1. Pivotal phase 3 data due July/August timeframe
2. They have enough cash to get through filing BLA for FDA Approval (in Q4) after data release.
3. They are continuing negotiations with potential partners, and believe the cash they now have gives them a much better position to that end.
These are the only relevant issues through the EOY. Beyond that while awaiting FDA approval, they will either have a partnership deal, buyout offer, or will need to raise more money for marketing, distribution, sales etc. to go it alone, which the additional shares can and will be used for, such the need arise. If approved, ONS-5010 will become the first line drug of choice for payor-mandated “step edit” in the US for retinal indications, estimated to be a $13 billion dollar market, and growing significantly.
My investment and target OTLK 40.000 shares x $25 = $1.000.000